PBS Of Australia To Get Advice On Erbitux, Gene-Testing Implications
This article was originally published in PharmAsia News
Australia's Pharmaceutical Benefits Advisory Committee is set to decide this week whether to recommend covering Merck Serono's Erbitux (cetuximab) cancer drug
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.